SURPASS-EARLY Tirzepatide Results

The new Annals On Call item is a journal companion piece, not a clinical trial report and not a new outcome estimate^[1]. The study it discusses is SURPASS-EARLY, an open-label randomized phase 4 trial in adults with type 2 diabetes diagnosed within the previous four years. At two years, tirzepatide lowered HbA1c more than intensified conventional care and produced greater reductions in weight and waist circumference^[2]. The result applies to a selected early-diabetes population already taking metformin. It does not show that every patient should switch treatments.

What Annals On Call is discussing

PubMed indexes the October 2026 Annals On Call item as a journal article and supplies no abstract. Its title points readers to the comparison between tirzepatide and intensified conventional care for poorly controlled type 2 diabetes^[1]. The underlying evidence comes from the separately published SURPASS-EARLY randomized trial. Keeping those two records separate matters: the companion item discusses the research, while the trial report supplies the patient outcomes.

SURPASS-EARLY enrolled 794 adults across 78 sites in 10 countries. Participants had been diagnosed with type 2 diabetes no more than four years earlier and had inadequate glycemic control despite diet, exercise and metformin. The registry specified a screening HbA1c from 7% to 9.5%^[3]. This was not a trial in people with long-standing diabetes, prior insulin use or established high cardiovascular risk.

The comparator was a treatment pathway

Investigators assigned participants to tirzepatide at 15 mg or the maximum tolerated dose, or to intensified conventional care. Conventional care could include glucose-lowering medicines used in local practice, including other GLP-1 receptor agonists but not tirzepatide^[2]. It was therefore a comparison with a flexible care strategy, not with one fixed medicine or placebo.

That design makes the trial relevant to a real treatment decision, but it complicates interpretation. The conventional-care group could receive different medicines depending on local guidance and clinical judgment. Readers should not assume that the reported average difference predicts the result against each possible comparator.

Eligibility narrows the result further. The registry excluded people with type 1 diabetes, prior injectable GLP-1 treatment or insulin use, a history of pancreatitis, and several advanced cardiovascular or eye conditions^[3]. It also required stable metformin treatment before assignment. Those choices created a study population suited to testing early intensification. They also mean the result cannot be carried unchanged into later-stage diabetes, acute illness or a switch from established insulin therapy. A clinician still has to match the evidence to the person in front of them.

HbA1c and body measurements favored tirzepatide

Mean HbA1c fell by 1.99 percentage points with tirzepatide and 1.32 points with intensified conventional care at two years. The estimated treatment difference was -0.68 percentage points. The 95% confidence interval ranged from -0.84 to -0.51, and the superiority test produced a P value below 0.001^[2]. Investigators first framed the primary objective as noninferiority for HbA1c change, with superiority assessed as a secondary objective.

The estimated treatment difference also favored tirzepatide by 8.0 kg for body weight and 6.2 cm for waist circumference. HbA1c below 5.7%, which the paper labels normoglycemia, was reached by 60.2% of the tirzepatide group and 24.0% of the conventional-care group^[2]. That threshold is a laboratory outcome within the trial. It does not mean diabetes was permanently cured or that treatment could be stopped.

Safety reporting needs the full paper

The PubMed abstract says gastrointestinal events were the most common adverse events in both groups, but it does not provide event-by-event rates or discontinuation counts^[2]. The abstract alone cannot support a detailed safety comparison. Treatment decisions also require the current product information, a patient's other medicines and clinical history.

The trial was funded by Eli Lilly. Several listed authors were company employees, and the trial registry names Lilly as lead sponsor^[2][3]. Sponsorship does not invalidate randomization, but it is relevant context for protocol design, analysis and reporting. The open-label design is another stated limitation because participants and investigators knew which treatment was assigned.

What the two-year result does not settle

The registry includes outcomes through week 208 and listed the study as active but not recruiting on its October 2026 version, with estimated completion in November 2027^[3]. The published two-year analysis therefore does not settle four-year durability. It also does not establish comparative cardiovascular benefit, rare harms or results in people excluded because of advanced complications or prior injectable treatment.

The practical reading is narrower. In adults with early type 2 diabetes that remained above target on metformin, the randomized strategy centered on tirzepatide produced larger average glycemic and weight changes over two years than flexible conventional intensification. Our tirzepatide evidence guide explains the medicine separately. Neither the trial nor the companion discussion supplies an individual treatment plan.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.